Clinical trials: SCLC, Extensive Stage
SCLC, Extensive-stage Small Cell Lung Cancer
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more…
- Trial name
- NCT07535359
- Testing
- Ifinatamab Deruxtecan
- Where
- 5 sites in United States
- Sponsor
- Daiichi Sankyo
Small Cell Lung Cancer
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.
- Trial name
- NCT00375193
- Testing
- Amrubicin
- Where
- 46 sites in United States, Netherlands and 1 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-Stage Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus…
- Trial name
- NCT06646276
- Testing
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin
- Where
- 183 sites in United States, Argentina and 24 more
- Volunteers
- 530 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).
- Trial name
- NCT06581380
- Testing
- JK-1201I, Topotecan
- Volunteers
- 394 people
- Sponsor
- JenKem Technology Co., Ltd.
Small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and…
- Trial name
- ALISCA-Lung1 (NCT06095505)
- Testing
- Alisertib
- Where
- 30 sites in United States
- Volunteers
- 120 people
- Sponsor
- Puma Biotechnology, Inc.
SCLC, Extensive Stage
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with…
- Trial name
- NCT07739758
- Testing
- YL201, Serplulimab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Lung Cancer
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00282022
- Testing
- laromustine
- Where
- 9 sites in United States
- Volunteers
- 87 people
- Sponsor
- Vion Pharmaceuticals
SCLC
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT05844150
- Testing
- PM8002, Platinum, Etoposide
- Where
- 17 sites in China
- Volunteers
- 50 people
- Sponsor
- Biotheus Inc.
Lung Cancer, Small Cell
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
- Trial name
- NCT00316186
- Testing
- topotecan, carboplatin
- Where
- 13 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
- Trial name
- DeLLphi-312 (NCT07005128)
- Testing
- Tarlatamab, Durvalumab, Carboplatin
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
- Trial name
- TITANS (NCT07652736)
- Testing
- Tislelizumab
- Where
- 6 sites in Spain
- Volunteers
- 440 people
- Sponsor
- BeOne Medicines
Small Cell Lung Cancer Extensive Stage
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body.
- Trial name
- NCT07227597
- Testing
- Gocatamig, I-DXd, Atezolizumab
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Conditions
- Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05882058
- Testing
- BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Small Cell
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
The purpose of the study is to determine whether the study drug ZK 219477 (also known as SH Y03757A) combined with cisplatin, is effective in the treatment of small cell lung cancer in patients who did not receive prior treatment…
- Trial name
- NCT00359359
- Testing
- Sagopilone (BAY86-5302, ZK 219477), Cisplatin
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Bayer
Small Cell Lung Cancer
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
- Trial name
- (DeLLphi-310) (NCT06898957)
- Testing
- YL201, Tarlatamab, Durvalumab
- Where
- 36 sites in United States, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- Amgen
Small-cell Lung Cancer
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg).
- Trial name
- PASSION (NCT03417895)
- Testing
- SHR-1210, Apatinib
- Where
- 2 sites in China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Small-cell Lung Cancer
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
This study is conducted in patients with advanced metastatic small cell lung cancer (SCLC). This study includes a single arm: the patients will receive HLX07 combination therapy with HLX10 and chemotherapy (carboplatin+etoposide)…
- Trial name
- NCT05354700
- Testing
- HLX07, HLX10, carboplatin and etoposide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Extensive-stage Small Cell Lung Cancer
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
This is a randomized, multi-center, open-label study of approximately 24 months duration (including follow up survival) to evaluate the safety and efficacy of obatoclax mesylate in combination with carboplatin and etoposide…
- Trial name
- NCT01563601
- Testing
- Obatoclax Mesylate, Carboplatine and Etoposide, Carboplatin and Etoposide
- Sponsor
- Cephalon